Intellia Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
The following table describes for the three months ended March 31, 2024 each trading arrangement under which the Company’s directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchaseor sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| David Lebwohl, M.D. (Executive Vice President, Chief Medical Officer) | Adoption (March 7, 2024) | Rule 10b5-1 trading arrangement | Sale | Until the earlier of (a) March 7, 2025; (b) the first date on which all trades have been executed or expired without execution; and (c) the date on which the plan holder gives notice to terminate the plan. | Up to 30,000 shares of the Company’s common stock |
| Frank Verwiel, M.D. (Director) | Adoption (March 7, 2024) | Rule 10b5-1 trading arrangement | Sale | Until the earlier of (a) July 8, 2024; (b) the first date on which all trades have been executed or expired without execution; and (c) the date on which the plan holder gives notice to terminate the plan. | Up to 1,504 shares of the Company’s common stock |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.